Such activation of the cGAS-STING pathway in DCs via various cancer-derived factors is crucial for initiating adaptive immune responses and enhancing antitumor immunity, highlighting the potential of the cGAS-STING pathway in therapeutic strategies aimed at harnessing innate immune responses to fight cancers [25–27]. This evidence concerns the gene CGAS and cancer.